Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 13.1% | 1.9% | 4.8% |
| 2025 |
|---|
| 4.8% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 13.1% | 1.9% | 4.8% |
| 2025 |
|---|
| 4.8% |
The Wasatch Micro Cap Fund posted a 1.88% return in Q4 2025, underperforming the Russell Microcap Growth Index's 2.14% return, primarily due to the fund's lack of exposure to early-stage biotechnology companies that dominated benchmark performance. For the full year 2025, the fund returned 4.83% versus the benchmark's 21.84%, as a historic low-quality market rally favored nonprofitable companies over the fund's high-quality holdings. Key contributors included Axogen, which received FDA approval expanding insurance coverage for its nerve allografts, Mama's Creations, which expanded through acquisition, and Castle Biosciences, which restored growth with new diagnostic tests. Detractors included Climb Global Solutions, Backblaze, and Vital Farms, which faced operational challenges. The managers maintained their disciplined approach, refusing to chase performance by rotating into low-quality names. They remain convinced that their focus on profitable, high-growth companies with strong fundamentals will drive long-term outperformance as markets eventually reward quality over speculation.
Focus on high-growth, high-quality microcap companies with differentiated business models and strong fundamentals, avoiding the market's preference for nonprofitable companies while positioning for long-term outperformance when quality is rewarded.
While it is impossible to predict the timing of when the market's preference for nonprofitable companies will be reversed, the managers remain convinced that the fundamental strength of their holdings will bode well for long-term performance. They believe many of the fund's biggest winners in Q4 2025 have significant room to advance further based on growth prospects and potential for expanded multiples as the market rewards profitability.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 22 2026 | 2025 Q4 | ADUS, AXGN, BLZE, CLMB, COCO, CSTL, ESQR, EZPW, MAMA, RDVT, SXI, TATT, VECO, VITL | Biotechnology, growth, healthcare, Microcap, profitability, Quality, underperformance |
AXGN MAMA CSTL CLMB |
The fund focuses on high-growth, high-quality companies with differentiated business models, avoiding the low-quality market rally that dominated 2025. The managers emphasize companies with strong… |
| Oct 20 2025 | 2025 Q3 | LMB, PAR, PI, PNTG, VITL | digital transformation, Energy Infrastructure, High Growth, Micro Caps, Sustainable Food |
WLDN PI VITL LMB PNTG |
The fund benefited from holdings in Vital Farms and Willdan Group as consumer demand for ethical food and energy infrastructure rose. Managers favor high-growth companies… |
| Jul 21 2025 | 2025 Q2 | AGYS, AXGN, GDYN, LMB, ROAD, WEAV | earnings growth, growth, innovation, Market cycles, Micro-Cap |
LMB ROAD AGYS GDYN |
The letter focuses on high-growth micro-cap companies with differentiated models and strong management teams. A risk-on environment favored lower-quality peers, creating relative underperformance. The fund… |
| Mar 31 2025 | 2025 Q1 | ADUS, BOW, EZPW, HCI, WEAV, XPOF | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
BiotechnologyHealthcare industry positioned for catch-up growth after several years of below-trend performance. Government spending expected to increase relative to feared cuts, with companies signaling improvement in revenue growth. Focus on 'picks & shovels' businesses serving the industry. |
Life Science Tools Pharmaceuticals CRO & CDMO Healthcare Research |
QualityThe company emphasizes investing in businesses with excellent economics, durable competitive advantages, and high-integrity management. This quality focus is evident in concentrated equity holdings and operating business acquisitions. |
Durable Advantages Management Quality Economic Moats Competitive Position | |
| 2025 Q3 |
InfrastructureDigital 9 Infrastructure holds telecom infrastructure assets including Arqiva stake. Despite poor 2025 performance, potential capital returns and asset sales could unlock value. Infrastructure assets provide defensive characteristics. |
Telecom Infrastructure Digital Infrastructure |
Sustainability2025 was one of the three hottest years ever recorded with climate-driven disasters causing significant costs. Despite political challenges, 84% of large companies maintained climate commitments and investor sentiment remained resilient with 70% committed to sustainability long-term. |
Climate Commitments Resilient Temperature Disasters | |
| 2025 Q2 |
Growth |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | Fund Letters | Ken Korngiebel | CLMB | Climb Global Solutions, Inc. | Information Technology | IT Distribution | Bear | NASDAQ | growth, Integration, Itdistribution, SMEs, Volatility | Login |
| Oct 20, 2025 | Fund Letters | Ken Korngiebel | WLDN | Willdan Group Inc. | Industrials | Consulting & Engineering | Bull | NASDAQ | Consulting, Contracts, data centers, efficiency, energy, Grid modernization, growth, Software, utilities | Login |
| Oct 20, 2025 | Fund Letters | Ken Korngiebel | PI | Impinj Inc. | Information Technology | Semiconductor Equipment | Bull | NASDAQ | Adoption, growth, Logistics, Margins, retail, RFID, semiconductors, supply chain, technology, Tracking | Login |
| Oct 20, 2025 | Fund Letters | Ken Korngiebel | VITL | Vital Farms Inc. | Consumer Staples | Food Products | Bull | NASDAQ | Branding, consumer trends, Eggs, Ethical sourcing, Food, growth, Margins, Sustainability, Transparency | Login |
| Oct 20, 2025 | Fund Letters | Ken Korngiebel | LMB | Limbach Holdings Inc. | Industrials | Engineering & Construction | Bull | NASDAQ | backlog, construction, growth, HVAC, infrastructure, Integration, Margins, Owner-direct, recovery | Login |
| Oct 20, 2025 | Fund Letters | Ken Korngiebel | PNTG | Pennant Group Inc. | Health Care | Health Care Facilities | Bull | NASDAQ | Acquisitions, Demographics, efficiency, healthcare, Hospice, recovery, Regulation, Reimbursement, valuation | Login |
| Jul 21, 2025 | Fund Letters | Ken Korngiebel | LMB | Limbach Holdings, Inc. | Industrials | Construction & Engineering | Bull | NASDAQ | Building Systems, HVAC, margin expansion, Owner-direct, strategic pivot, turnaround | Login |
| Jul 21, 2025 | Fund Letters | Ken Korngiebel | ROAD | Construction Partners, Inc. | Industrials | Construction & Engineering | Bull | NASDAQ | earnings growth, infrastructure spending, M&A, Road Construction, Roll-up | Login |
| Jul 21, 2025 | Fund Letters | Ken Korngiebel | AGYS | Agilysys, Inc. | Information Technology | Software | Bull | NASDAQ | contrarian, Execution Issues, Hospitality Software, Management Meeting, market share | Login |
| Jul 21, 2025 | Fund Letters | Ken Korngiebel | GDYN | Grid Dynamics Holdings, Inc. | Information Technology | IT Services | Bear | NASDAQ | Digital transformation, Generative Ai Risk, IT services, macro headwinds, Outsourcing | Login |
| Jan 22, 2026 | Fund Letters | Ken Korngiebel | AXGN | Axogen, Inc. | Health Care | Health Care Equipment & Supplies | Bull | NASDAQ | Exclusivity, Fdaapproval, growth, Medicaldevices, Reimbursement | Login |
| Jan 22, 2026 | Fund Letters | Ken Korngiebel | MAMA | Mama's Creations, Inc. | Consumer Staples | Packaged Foods | Bull | NASDAQ | Acquisitions, Consumertrends, Conveniencefood, Distribution, Margins | Login |
| Jan 22, 2026 | Fund Letters | Ken Korngiebel | CSTL | Castle Biosciences, Inc. | Health Care | Diagnostics & Research | Bull | NASDAQ | cashflow, diagnostics, Oncology, Reimbursement, valuation | Login |
| TICKER | COMMENTARY |
|---|---|
| AXGN | New to the strategy was Axogen, Inc., which develops technologies for peripheral nerve regeneration and repair from injuries caused by trauma, chronic conditions, or surgical procedures. Its flagship product, Avance Nerve Graft, is a decellularized human nerve allograft that preserves native nerve microarchitecture while eliminating immune rejection risk. It is the only FDA-approved implantable biological nerve allograft on the market. |
| BLZE | Cloud-based data storage company Backblaze provides data storage at a fraction of the price of the cloud services arms of companies like Meta, Alphabet and Amazon, making it more affordable for its customers to move data in and out of these hyperscalers' closed ecosystems. While we view this value proposition favorably, Backblaze is in the process of executing a pivot toward focusing on more upscale, large-enterprise clients, which will require a more intensive 'hands-on' approach to sales and servicing. In our experience, such transitions can take longer than anticipated and present a challenge to financial results, and we exited our position in the company for now. |
| CLMB | Software distribution company Climb Global Solutions has a strong track record of bringing new products to small and medium-sized businesses that require higher levels of technical support than the large enterprise market. Its results can be somewhat 'lumpy' depending on the timing of larger deals, and recognized revenue has also been impacted by the cost of integrating a handful of acquisitions in recent years. While the stock performed poorly in the quarter, we view Climb as positioned to post double-digit year-over-year growth over a significant runway while it continues to reinvest in its business. |
| COCO | Coconut beverage producer Vita Coco returned nearly +25% for the quarter on better-than-expected earnings and reduced concerns around potential tariff risks. |
| CSTL | Castle Biosciences is a provider of diagnostic tests, with its largest product targeting melanoma. The company also offers a newer test for squamous cell carcinoma, another type of skin cancer. Castle has been challenged by reimbursement issues for the squamous cell test, which has weighed on the stock as growth has matured for its traditional lead product addressing melanoma. The company has developed a third test targeting a form of esophageal cancer which can result from untreated gastroesophageal reflux disease. The new product, combined with reinvigorated sales efforts around the melanoma test, has helped Castle restore its growth trajectory and outlook for positive cash flow. |
| MAMA | stocks scaling very nicely and entering the small-cap sweet spot (REAL, MAMA, CBLL, KRMD). |
| RDVT | Red Violet (RDVT – Ugly Duckling) is one of our five largest holdings in alphabetical order. Companies like Red Violet and Par Technology, one of which has legally privileged and proprietary data streams and the other which creates and manages mission critical, intricate databases for transaction flows, are just a couple of the countless examples of babies being thrown out with the bathwater. |
| TATT | We added 8 new positions in Q4: one each in telecommunications (Applied Optoelectronics), industrials (TAT Technologies) |
| VITL | Vital Farms is a provider of specialty eggs and butter from small farms and pasture-raised animals. Consumers are increasingly focused on how the food they eat is sourced, both with respect to the health implications and how the animals involved are treated. As the fourth quarter began, the company went live with a new enterprise resource planning (ERP) system designed to automate manual processes and provide a scalable platform to support rapid growth. Vital experienced some hiccups in implementing the ERP system, which weighed on volumes and led management to lower full-year guidance in December. In our view, however, the increasing focus on higher quality food sourced sustainably and ethically is a durable trend that will largely resist any temptation to trade down on eggs. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||